

BIONEER

IR Brief

September
2026
vol. 36

Drug Delivery Platform SAMiRNA

ExiProgen™

Exicycler V5™



Bioneer X SiRNAgen Therapeutics Drug Development Paired with Diagnostic Instruments

- SAMiRNA-Based RNAi Drug Candidate SRN-001
- "From Drug to Diagnostic" — One Team at CPHI

Drug development technology that treats disease using RNA, and diagnostic technology that confirms whether the treatment works — the two look separate, but in drug development they are inseparable. That is why Bioneer and subsidiary SiRNAgen Therapeutics ran side-by-side booths at CPHI & Hi Korea 2026, held August 25–27.



At the exhibition, SiRNAgen presented under the theme "Innovating RNAi Therapeutics with SAMiRNA," unveiling research on SRN-001, built on its SAMiRNA® delivery platform. Beyond the lead indication of idiopathic pulmonary fibrosis (IPF), data supported potential expansion into kidney fibrosis, liver fibrosis, and MASH/MASLD — all linked via AREG (amphiregulin) suppression.



The Invisible Measurement Behind Every New Drug

Before a candidate can be called effective, it must pass a chain of validation — from choosing a target gene to confirming its expression is suppressed inside the cell. Bioneer's instruments support each step.



ExiProgen™

1. Target Protein Research

The first step. Once a target gene or protein is chosen, both RNAi and antibody drugs need the target protein itself — RNAi to study or screen candidates, antibody drugs to confirm binding — both requiring pure recombinant antigen protein. ExiProgen speeds this up by rapidly expressing and purifying it.



EcoQprep

2. Sample Preparation After Treatment

After a candidate is applied to cells, mRNA is extracted to measure its effect. EcoQprep is used at this step, right after cell treatment.



Exicycler V5™

3. Quantitative Efficacy Analysis

Using extracted mRNA to quantify how much target-gene expression has decreased. The Exicycler V5 real-time qPCR system measures knockdown efficiency, response biomarkers, and PK/PD data.

Bioneer also introduced its oligo CDMO manufacturing for preclinical/clinical oligo drug substances, and biomarker panel kits for functional-ingredient discovery aimed at health-food companies.

Presenting the Drug Pipeline Alongside Analytical Infrastructure

By placing SiRNAgen's pipeline alongside Bioneer's analytical instruments, the joint booth showed what analytical technology supports an RNAi drug from discovery through preclinical and clinical development. Discussions covered preclinical sample quotes, equipment inquiries, and biomarker analysis for health-food applications.



Bioneer, Nepal Health Authorities, WHO, WFP Discuss TB Diagnostics Rapid Pediatric TB Diagnostics to Expand Health Ties

On August 19, officials from Nepal's National Planning Commission, the Ministry of Social Development's Department of Health Services, the WHO Nepal Country Office, and the UN World Food Programme's Nepal office visited Bioneer HQ to discuss TB, pediatric TB, and infectious disease diagnostics cooperation.

A New Alternative for TB Diagnosis in Low- and Middle-Income Countries

IRON-qPCR™ · RFIA Kit

Bioneer highlighted its next-gen molecular diagnostic platform IRON-qPCR™ and its TB kit, the RFIA Kit.

From a single sample, the system detects *M. tuberculosis* and resistance across four drug classes — rifampicin, isoniazid, fluoroquinolones, aminoglycosides — within 40 minutes, an alternative that cuts treatment delays versus methods needing repeat testing. Ambient-temperature shipping and a 24-month shelf life suit countries with limited cold-chain infrastructure.



The Challenge of Diagnosing Pediatric TB

Behind the interest in fast, simple diagnostics lies a gap in pediatric TB diagnosis in Nepal. Rabin Gautam, WHO Nepal's national TB officer, said Nepal's pediatric TB notification rate is 5.6%, well below the 10–20% expected in high-burden countries. Nearly half of pediatric TB cases worldwide go undiagnosed, partly because sputum collection is hard in young children, leaving gastric aspirate or stool as the main alternatives; Nepal uses stool-based testing but lacks nationwide coverage, and WHO's adult tongue-swab method isn't yet used for children. Chairman Park Han-oh said, "Clinical evaluation of tongue-swab and stool sampling for pediatric TB is planned in Uganda with the Korea Institute of Tuberculosis (KIT), to validate it as a practical solution."

Reviewing a Path to WHO-PQ and Global Fund Procurement Listing

The parties discussed listing on the WHO Prequalification (WHO-PQ) and Global Fund (the international AIDS/TB/malaria financing body) procurement lists, key to Nepal's market entry since its TB kits are procured via Global Fund financing rather than government budget.

Bioneer is running global clinical evaluations across six countries — with FIND and supported by the RIGHT Foundation — to pursue WHO-PQ listing for the RFIA Kit, which detects both multidrug- and extensively drug-resistant TB, aiming next for Global Fund listing and entry into public procurement markets including Nepal.

The meeting also touched on diagnostics cooperation for febrile and waterborne diseases like dengue, cholera and salmonella, and possible use of Bioneer's ExiStation™ FA 96 for HIV-1, HBV and HCV testing in Nepal.



CosmeRNA At Korea's 24th Hair Forum, 2026

▲ Bioneer presents at the Hair Forum free-paper session

Bioneer's independently developed RNA-based hair and scalp care line, CosmeRNA, took part in the Korean Hair Research Society's Hair Forum, presenting its latest research.


The Hair Forum brings together Korean dermatologists and hair research specialists to share the latest clinical and academic research on hair loss and scalp conditions.

In the free-paper session, Chairman Park Han-oh spoke on "A New Approach to Hair Loss Treatment Through mRNA Regulation of Follicular Cells," introducing SAMiRNA technology and CosmeRNA, along with findings published in JAAD and other journals. The Q&A covered delivery mechanism, real-world application, and the platform's expansion potential.

At its booth, Bioneer introduced CosmeRNA's technology to Korean hair and scalp

specialists and dermatologists, focusing on clinical results and applications. CosmeRNA has also been presented at international meetings including WCHR.

Through this Hair Forum appearance, Bioneer connected directly with domestic specialists to share its research. The company plans to keep expanding academic exchange at home and abroad.





Bioneer Signs MOU with Daejeon Beauty Agency, Korean Society of Cosmetology at K-Beauty Congress

- ▲ Bioneer introduces CosmeRNA to K-beauty academia
- ▲ Park Han-oh keynotes on bio-innovation and K-beauty

On August 4, Bioneer joined the 2026 K-Beauty Academic Congress at the Daejeon Beauty Industry Promotion Agency, signing an MOU with the Agency and the Korean Society of Cosmetology.

Through the MOU, Bioneer plans to strengthen ties between beauty academia and industry, and expand collaboration applying its RNA technology to K-beauty.

The congress drew participants from beauty societies, universities, industry and research institutions nationwide, including the Korean Society of Cosmetology, the Korean Society

of Aesthetics and Cosmetics, and several other national beauty associations.

Chairman Park Han-oh delivered a keynote, "The Future of K-Beauty Opened by Bio-Innovation Technology," describing a shift from experience-based hair and scalp care toward precision care grounded in science and biotechnology.

CosmeRNA ART
SCALP REVITALIZING SERUM
코스메르나 에어피라이 스칼프 리바이탈리징 세럼

The keynote introduced Bioneer's RNA research and CosmeRNA, sharing follicle-regulation approaches and clinical results. It also cited CosmeRNA's overseas market entry as an example of biotech's potential in K-beauty.

Bioneer ran a CosmeRNA promotional booth at the event, showcasing products and expert care programs following the keynote. The booth drew steady visits

and inquiries.

Through this MOU and congress participation, Bioneer plans to strengthen ties with beauty academia and professionals, expanding its role in hair and scalp care via its RNA platform.



▲ Bioneer's booth at the 2026 K-Beauty Academic Congress

AceBiome at Hi Korea 2026 Presenting a Life-Stage Health Portfolio

CPHI



AceBiome
Korea
BNR Thin R
Weight Management
Probiotic, BNR17


Korea

▲ Expanding BNR17 research and partnerships

AceBiome completed its participation in Hi(Health Ingredients) Korea 2026, held August 25–27 at COEX Seoul. At the exhibition, AceBiome presented its microbiome research and a product portfolio built around life-stage health needs.

At its booth, AceBiome showcased BNRThin R, BNR Queen, and AnaParactin for Joints, covering body-fat and gut health, women's health, and joint and bone health across age groups from children to seniors.

Flagship product BNRThin R is built on AceBiome's core ingredient, *Lactobacillus gasseri* BNR17, a patented strain from Korean breast milk recognized in Korea for body-fat reduction. It combines BNR17 with prebiotics for body-fat and gut health.



The exhibition also featured new research on older-adult health. An eight-week pilot trial in adults aged 65–74 showed improvements in SPPB scores, lean body mass and lower-body muscle mass, with reductions in some body-fat measures including visceral fat. Further research is needed to expand the functional claims.

BNR Queen, for middle-aged women, combines BNR17 and Sophora japonica extract with vitamins D and A, zinc and selenium, addressing body-fat, gut and menopausal health — extending AceBiome's portfolio across the female life cycle.

AceBiome also shared BNR17 research on women's health: a preclinical ovariectomized-model study observed changes in bone density, pain sensitivity, vaginal epithelial keratinization and serotonin 2A markers. Findings remain preclinical, requiring further human research.

AnaParactin for Joints uses Andrographis paniculata extract (ParActin®) with vitamins K2 and D3 for joint and bone health, spanning younger to older consumers.

Throughout the exhibition, AceBiome shared research and product strengths with domestic and international industry contacts and partners, exploring new distribution and joint-business opportunities.

Going forward, the company plans to extend BNR17 R&D into women's and senior health, build out its life-stage portfolio, and link ingredient research with commercialization for new market opportunities.